Welcome to our dedicated page for Cosmos Health SEC filings (Ticker: COSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cosmos Health Inc. filings document the public-company record of a Nevada healthcare issuer with common stock listed on the Nasdaq Capital Market under COSM. Recent Form 8-K reports cover operating results, Regulation FD disclosures, Nasdaq minimum-bid-price compliance matters, board appointments, annual-meeting voting results and capital-structure proposals involving common stock and blank-check preferred stock.
The filing record also includes a Form 12b-25 notice for a delayed annual report and disclosures tied to business performance across contract manufacturing, wholesale distribution, proprietary nutraceutical brands and research and development. These documents address governance, listing status, share authorization, financial reporting timing and the company's operating subsidiaries and product portfolio.
Cosmos Health Inc. (COSM) filed a Form 8-K stating that on November 17, 2025 it issued a press release announcing its financial results for the quarter and nine months ended September 30, 2025. The press release is included as Exhibit 99.1 and provides the detailed financial figures and commentary. The company notes that the information in Items 2.02 and 7.01 and in Exhibit 99.1 is being furnished, not filed, under securities law, which limits certain legal liabilities and how the information may be incorporated into other filings.
Cosmos Health Inc. filed a replacement Form S-3 shelf registering up to $200,000,000 of common stock, preferred stock, warrants, units and subscription rights to be offered from time to time after effectiveness. The filing also includes a prospectus supplement for an at-the-market offering of up to $100,000,000 of common stock through A.G.P., which will earn a 3% commission on gross proceeds.
The company notes that, as of November 6, 2025, 34,919,920 shares of common stock were outstanding, with 26,274,546 held by non‑affiliates. Our common stock last closed at $0.67 on November 6, 2025, and trades on Nasdaq as “COSM.”
Unless otherwise indicated in a supplement, net proceeds are intended for the acquisition of crypto assets as a treasury asset and for general corporate purposes and working capital. Sales under the ATM may occur at market prices “from time to time,” subject to Securities Act Rule 415 and public float constraints.
Cosmos Health Inc. (COSM) reported that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement. Nasdaq notified the company that the closing bid price of its common stock was at least $1.00 per share for 18 consecutive business days, from September 22, 2025 to October 15, 2025, and the matter is now closed.
The update follows a prior notice on November 6, 2024 that COSM was below the $1.00 threshold for 30 consecutive business days. The company furnished a press release about the compliance status under Regulation FD.
Cosmos Health Inc. reported that its Board appointed Theodoros C. Karkantzos as a director effective September 30, 2025. He was elected at the annual general meeting on the same date, with an initial term running until the company’s 2026 annual meeting of stockholders. On September 30, 2025, he was also named to the Board’s Nominating and Corporate Governance Committee.
Mr. Karkantzos has over 15 years of experience in investment and business development, including co-founding Blue Dot Digital Agency and working as a private investor across real estate, healthcare, equities, and hospitality in Europe. He holds an MPhil in Real Estate Finance from the University of Cambridge and a BSc in Management from the University of Warwick.
He will receive a $5,000 cash fee for serving on the Nominating & Corporate Governance Committee and an annual Board participation cash fee of $10,000, plus an equity grant under the company’s 2025 Omnibus Incentive Plan. The company notes there was no arrangement with any other person regarding his appointment and no related-party transactions involving him or his immediate family beyond consulting services previously provided without cash or equity compensation.
Cosmos Health Inc. reported the results of its 2025 Annual Meeting of Stockholders held on September 30, 2025. Stockholders elected six directors to serve until the next annual meeting and reappointed the company’s independent registered public accounting firm. Quorum was reached with 15,983,371 shares present, about 53% of the 30,127,379 common shares outstanding on the record date.
Stockholders authorized the board to implement a reverse stock split of the outstanding common stock at its discretion. They also approved the issuance of shares of common stock issuable upon conversion of notes in compliance with Nasdaq Listing Rule 5635(d) and adopted the 2025 Equity Omnibus Plan. In addition, stockholders approved, on an advisory basis, the company’s executive compensation and chose a three-year frequency for future “say on pay” votes.
Importantly, stockholders approved an amendment to the Articles of Incorporation to increase authorized capital to 1,500,000,000 shares of common stock and 300,000,000 shares of blank check preferred stock, with the amendment becoming effective upon filing with the Nevada Secretary of State.
Cosmos Health Inc. filed a current report to inform investors that its Chief Executive Officer has released an annual letter to shareholders for the year ended December 31, 2024. The letter, dated September 29, 2025, has been made available and is attached as Exhibit 99.1, providing additional context on the company’s strategy and outlook.
The company emphasizes that the CEO letter includes forward-looking statements about anticipated strategic plans and related outcomes, which are subject to risks and uncertainties. These statements are described as reflecting current intentions and expectations and may differ from actual future results. The information in the CEO letter and this report is being furnished under Regulation FD and is not deemed filed for liability purposes under the Securities Exchange Act.
Cosmos Health Inc. filed Amendment No. 1 to its shelf registration statement No. 333-290420 as an exhibits-only update. The company is adding as exhibits a Secured Convertible Promissory Note issued to M2B Funding Corp. dated June 9, 2025 and an August 6, 2025 amendment to that note, while leaving the prospectus unchanged and omitted from this filing.
The amendment also restates standard sections on offering expenses, indemnification of directors and officers under Nevada law and the company’s governing documents, and customary Securities Act undertakings for shelf offerings. The document is signed on behalf of Cosmos Health by Chief Executive Officer Grigorios Siokas and other senior officers and directors on September 22, 2025.
Cosmos Health Inc. filed Amendment No. 1 to its shelf registration statement No. 333-290420 as an exhibits-only update. The company is adding as exhibits a Secured Convertible Promissory Note issued to M2B Funding Corp. dated June 9, 2025 and an August 6, 2025 amendment to that note, while leaving the prospectus unchanged and omitted from this filing.
The amendment also restates standard sections on offering expenses, indemnification of directors and officers under Nevada law and the company’s governing documents, and customary Securities Act undertakings for shelf offerings. The document is signed on behalf of Cosmos Health by Chief Executive Officer Grigorios Siokas and other senior officers and directors on September 22, 2025.
Cosmos Health Inc. filed Amendment No. 1 to its shelf registration statement No. 333-290420 as an exhibits-only update. The company is adding as exhibits a Secured Convertible Promissory Note issued to M2B Funding Corp. dated June 9, 2025 and an August 6, 2025 amendment to that note, while leaving the prospectus unchanged and omitted from this filing.
The amendment also restates standard sections on offering expenses, indemnification of directors and officers under Nevada law and the company’s governing documents, and customary Securities Act undertakings for shelf offerings. The document is signed on behalf of Cosmos Health by Chief Executive Officer Grigorios Siokas and other senior officers and directors on September 22, 2025.
Cosmos Health Inc. filed Amendment No. 1 to its shelf registration statement No. 333-290420 as an exhibits-only update. The company is adding as exhibits a Secured Convertible Promissory Note issued to M2B Funding Corp. dated June 9, 2025 and an August 6, 2025 amendment to that note, while leaving the prospectus unchanged and omitted from this filing.
The amendment also restates standard sections on offering expenses, indemnification of directors and officers under Nevada law and the company’s governing documents, and customary Securities Act undertakings for shelf offerings. The document is signed on behalf of Cosmos Health by Chief Executive Officer Grigorios Siokas and other senior officers and directors on September 22, 2025.
Cosmos Health Inc. filed Amendment No. 1 to its shelf registration statement No. 333-290420 as an exhibits-only update. The company is adding as exhibits a Secured Convertible Promissory Note issued to M2B Funding Corp. dated June 9, 2025 and an August 6, 2025 amendment to that note, while leaving the prospectus unchanged and omitted from this filing.
The amendment also restates standard sections on offering expenses, indemnification of directors and officers under Nevada law and the company’s governing documents, and customary Securities Act undertakings for shelf offerings. The document is signed on behalf of Cosmos Health by Chief Executive Officer Grigorios Siokas and other senior officers and directors on September 22, 2025.
Cosmos Health Inc. is registering 78,637,352 shares of common stock for resale by investors that may receive these shares upon converting the company’s secured convertible notes. The shares include 72,159,091 shares tied to an August 2025 senior secured convertible note and 6,478,261 shares tied to a June 2025 secured convertible note. Based on a last sale price of $0.9319 on September 18, 2025, the registered shares have an indicated value of about $73.3 million. All sale proceeds will go to the selling stockholders, not the company. As of September 18, 2025, Cosmos had 31,013,876 common shares outstanding and is asking stockholders to approve an increase in authorized common shares to 1.5 billion. Conversion of the notes is subject to 4.99% or 9.99% beneficial ownership limits and could significantly increase the tradable float, with the company warning of high risk, potential dilution and stock price volatility.
Cosmos Health Inc. is registering 78,637,352 shares of common stock for resale by investors that may receive these shares upon converting the company’s secured convertible notes. The shares include 72,159,091 shares tied to an August 2025 senior secured convertible note and 6,478,261 shares tied to a June 2025 secured convertible note. Based on a last sale price of $0.9319 on September 18, 2025, the registered shares have an indicated value of about $73.3 million. All sale proceeds will go to the selling stockholders, not the company. As of September 18, 2025, Cosmos had 31,013,876 common shares outstanding and is asking stockholders to approve an increase in authorized common shares to 1.5 billion. Conversion of the notes is subject to 4.99% or 9.99% beneficial ownership limits and could significantly increase the tradable float, with the company warning of high risk, potential dilution and stock price volatility.
Cosmos Holdings Inc. (COSM) discusses a proposed Reverse Stock Split and related considerations. The filing notes factors that could affect the historical and future trading price and volume of the Common Stock, including the anticipated market impact of the Reverse Stock Split and the company's ability to remain listed on Nasdaq. The company lists intended uses of any equity restructuring or capital-raising, including raising capital to fund operations and continue as a going concern, establishing strategic relationships, providing equity incentives to employees, officers or directors, and expanding via acquisitions or new product lines. The filing also explains that holders of registered book-entry shares need take no action to receive post-split shares; a transaction statement will be sent by the transfer agent after the Effective Date.
Andreas Bovopoulos reported beneficial ownership of 1,453,044 shares of Cosmos Health Inc. common stock, representing 4.823% of the class. The filing is a Schedule 13G/A dated for the event on 08/13/2025 and signed 08/19/2025. Bovopoulos reports sole voting and dispositive power over all shares and certifies the shares were not acquired to influence control of the issuer. The issuer's principal executive office is listed in Thessaloniki, Greece. The disclosure classifies this holding as ownership of 5 percent or less of the class and indicates no group affiliation, no subsidiary acquisition, and no holdings on behalf of another person.